VTGN
VistaGen Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.24
−1.38%Year over year
Reported trailing growth
- Revenue
- +287.3%
- EBITDA
- -17.2%
- EBIT
- -16.8%
- EPS
- +5.0%
- Free cash flow
- -24.1%
- Operating cash flow
- -24.4%
Forward estimates
Based on analyst estimates
- Revenue
- -3.8%
- EBITDA
- +28.9%
- EPS
- +33.5%
Three-year CAGR
- Revenue
- +9.2%
- EBITDA
- -40.6%
- EBIT
- -28.9%
- Net income
- -35.5%
- EPS
- -9.6%
- Free cash flow
- -57.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026